These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7789721)

  • 21. Dopaminergic antagonism of L-5-hydroxytryptophan-induced myoclonic jumping behavior.
    Weiner WJ; Carvey PM; Nausieda PA; Klawans HL
    Neurology; 1979 Dec; 29(12):1622-5. PubMed ID: 41197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral and biochemical aspects of neuroleptic-induced dopaminergic supersensitivity: studies with chronic clozapine and haloperidol.
    Seeger TF; Thal L; Gardner EL
    Psychopharmacology (Berl); 1982; 76(2):182-7. PubMed ID: 6805029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.
    Montanaro N; Dall'Olio R; Gandolfi O; Vaccheri A
    Eur J Pharmacol; 1982 Jun; 81(1):1-9. PubMed ID: 6889533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
    Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
    Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Separation of dopaminergic and serotonergic inhibitory mechanisms in the mediation of estrogen-induced lordosis behaviour in the rat.
    Fernández-Guasti A; Ahlenius S; Hjorth S; Larsson K
    Pharmacol Biochem Behav; 1987 May; 27(1):93-8. PubMed ID: 2956611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral evidence for dopamine receptor subsensitivity following chronic haloperidol.
    Lynch MR
    Neuropsychobiology; 1990-1991; 24(2):102-8. PubMed ID: 2151972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carbamazepine reduces dopamine-mediated behavior in chronic neuroleptic-treated and untreated rats: implications for treatment of tardive dyskinesia and hyperdopaminergic states.
    LaHoste GJ; Wigal T; King BH; Schuck SEB; Crinella FM; Swanson JM
    Exp Clin Psychopharmacol; 2000 Feb; 8(1):125-132. PubMed ID: 10743913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Behavioral effects of chronic apomorphine, and D-1/D-2 dopamine receptor activities in rats].
    Minematsu N
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Jun; 15(3):247-52. PubMed ID: 7584718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment.
    Smith RC; Davis JM
    Psychopharmacol Commun; 1975; 1(3):285-93. PubMed ID: 1241453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of bradykinesia induction by SM-9018, a novel 5-HT2 and D2 receptor antagonist, using the mouse pole test.
    Ohno Y; Ishida K; Ikeda K; Ishibashi T; Okada K; Nakamura M
    Pharmacol Biochem Behav; 1994 Sep; 49(1):19-23. PubMed ID: 7816873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroleptic-induced reduction of quipazine-elicited head-twitches in rats: possible involvement of striatal dopaminergic supersensitivity.
    Dall'Olio R; Vaccheri A; Gandolfi O; Roncada P; Montanaro N
    Pharmacol Biochem Behav; 1988 Dec; 31(4):941-4. PubMed ID: 2908069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Behavioural correlates of modified dopaminergic/anticholinergic responses following chronic treatment with neuroleptic agents of differing activity spectra.
    Costall B; Naylor RJ; Owen RT
    Eur J Pharmacol; 1978 Mar; 48(1):29-36. PubMed ID: 25189
    [No Abstract]   [Full Text] [Related]  

  • 34. The specificity of neuroleptic- and methysergide-induced behavioral hypersensitivity.
    Klawans HL; D'amico DJ; Nausieda PA; Weiner WJ
    Psychopharmacology (Berl); 1977 Nov; 55(1):49-52. PubMed ID: 414261
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of thioridazine on haloperidol induced behavioral hypersensitivity.
    Klawans HL; Carvey PM; Nelson D; Tanner CM; Goetz CG
    Life Sci; 1986 May; 38(19):1707-14. PubMed ID: 3702600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of 5-HT1A and 5-HT2A/2C receptor modulation on neuroleptic-induced vacuous chewing movements.
    Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2001 Sep; 428(1):81-6. PubMed ID: 11779040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic nicotine treatment potentiates behavioral responses to dopaminergic drugs in rats.
    Suemaru K; Gomita Y; Furuno K; Araki Y
    Pharmacol Biochem Behav; 1993 Sep; 46(1):135-9. PubMed ID: 7902980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.
    Norman MH; Rigdon GC; Navas F; Cooper BR
    J Med Chem; 1994 Aug; 37(16):2552-63. PubMed ID: 7914539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine2A receptor antagonist, in rats.
    Okuyama S; Chaki S; Kawashima N; Suzuki Y; Ogawa S; Kumagai T; Nakazato A; Nagamine M; Yamaguchi K; Tomisawa K
    Br J Pharmacol; 1997 Jun; 121(3):515-25. PubMed ID: 9179395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of dopaminergic supersensitivity by a single dose of amphetamine.
    Haracz JL; Tseng LF
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Aug; 313(2):131-3. PubMed ID: 6106902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.